Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
Ding Z, Wu H, Zeng Y, Kuang M, Yang W, Meng Z, Chen Y, Hao C, Zou S, Sun H, Liu C, Lin K, Shi G, Wang X, Fu X, Chen R, Chen Y, Liang R, Kano T, Pan H, Yang S, Fan J, Zhou J. Ding Z, et al. Among authors: zeng y. Hepatol Int. 2023 Feb;17(1):180-189. doi: 10.1007/s12072-022-10421-9. Epub 2022 Oct 18. Hepatol Int. 2023. PMID: 36258065 Free PMC article. Clinical Trial.
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y, Zhu X, Liu J, Zhong J, Zhang W, Shen S, Jin R, Liu H, Ye F, Hu K, Xu D, Zhang Y, Chen Z, Xing B, Zhou L, Chen Y, Zeng Y, Liang X, Kuang M, Song T, Xiang B, Wang K, Sun H, Xu L; China Liver Cancer Study Group Young Investigators (CLEAP). Pan Y, et al. Among authors: zeng y. Front Immunol. 2023 Apr 26;14:1138355. doi: 10.3389/fimmu.2023.1138355. eCollection 2023. Front Immunol. 2023. PMID: 37180173 Free PMC article.
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Lin KY, Lin ZW, Chen QJ, Luo LP, Zhang JX, Chen JH, Wang K, Tai S, Zhang ZB, Wang SF, Zhang JY, You WY, Wang B, You PH, Lin KC, Yang T, Zeng YY. Lin KY, et al. Hepatol Int. 2023 Dec;17(6):1477-1489. doi: 10.1007/s12072-023-10561-6. Epub 2023 Jun 29. Hepatol Int. 2023. PMID: 37382760
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.
Liu J, Zhu X, Pan Y, Zhong J, Jin R, Zheng X, Zhang W, Hu K, Ma J, Shi X, Liu H, Yang X, Xu D, Ma C, Chen J, Wang D, Wang X, Li Z, Zhao L, Zhang L, Li T, Liu F, Tan G, Xing B, Zhao H, Zeng Y, Zhang S, Zhang L, Zhou L, Song T, Yang W, Liang X, Xiang B, Xu L, Sun H, Wang K. Liu J, et al. Among authors: zeng y. Oncologist. 2024 Apr 4;29(4):e487-e497. doi: 10.1093/oncolo/oyad277. Oncologist. 2024. PMID: 37874924 Free PMC article.
14,228 results
You have reached the last available page of results. Please see the User Guide for more information.